# ClinicalTrials.gov record NCT02064036

> PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02064036-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-10-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02064036-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02064036-leuprolide-v1.json
- Content SHA-256: `dd57e0bd2b2a5c6947ffa98864893d5b5ac37f78c83b908a5f20403785c1fd62`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02064036 ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`](#source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72))

## Sources

<a id="source-ctg-observation-nct02064036-2022-10-18-7f576b6f5d72"></a>
- **ClinicalTrials.gov record NCT02064036 · retained source version 2022-10-18:7f576b6f5d726378b095f53e246fc9a3b50eb12e4bc04a5ce49fd642678befc2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02064036) (`ctg-observation-nct02064036-2022-10-18-7f576b6f5d72`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02064036." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02064036-leuprolide-v1.json SHA-256: dd57e0bd2b2a5c6947ffa98864893d5b5ac37f78c83b908a5f20403785c1fd62.